PGE1
PGE1 Brand names, PGE1 Analogs
PGE1 Brand Names Mixture
- No information avaliable
PGE1 Chemical_Formula
C20H34O5
PGE1 RX_link
http://www.rxlist.com/cgi/generic/alprostadil.htm
PGE1 fda sheet
PGE1 msds (material safety sheet)
PGE1 Synthesis Reference
No information avaliable
PGE1 Molecular Weight
354.481 g/mol
PGE1 Melting Point
115 - 116 oC
PGE1 H2O Solubility
26.7 mg/L
PGE1 State
Solid
PGE1 LogP
2.983
PGE1 Dosage Forms
Liquid; Powder for solution; Solution; Suppository
PGE1 Indication
For palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Also for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.
PGE1 Pharmacology
Alprostadil (prostaglandin E1) is produced endogenously to relax vascular smooth muscle and cause vasodilation. In adult males, the vasodilatory effects of alprostadil on the cavernosal arteries and the trabecular smooth muscle of the corpora cavernosa result in rapid arteriolar inflow and expansion of the lacunar spaces within the corpora. As the expanded corporal sinusoids are compressed against the tunica albuginea, venous outflow through the subtunical vessels is impeded and penile rigidity develops. This is referred to as the corporal veno-occlusive mechanism. In infants, the vasodilatory effects of alprostadil increase pulmonary or systemic blood flow.
PGE1 Absorption
The absolute bioavailability of alprostadil has not been determined.
PGE1 side effects and Toxicity
Oral, mouse: LD50 = 186 mg/kg; Oral, rat: LD50 = 228 mg/kg. Apnea, bradycardia, pyrexia, hypotension, and flushing may be signs of drug overdosage.
PGE1 Patient Information
PGE1 Organisms Affected
Humans and other mammals
